Straight leg raising test and lumbar cerebrospinal fluid levels of vasoactive intestinal polypeptide and somatostatin in patients with low back pain

What Was Tested

This clinical trial paper looks at Somatostatin and VIP (Vasoactive Intestinal Peptide).

The study sought to examine correlations, if any, between a positive straight leg raising test and cerebrospinal fluid neuropeptide levels.

Who Took Part

The abstract describes 77 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

Straight leg raising was recorded before myelography in 77 patients.

The straight leg raising test was recorded for all patients before a myelography examination was performed because of intractable leg pain symptoms.

How the Study Was Run

At myelography, samples of cerebrospinal fluid were drawn and later analyzed for neuropeptides vasoactive intestinal polypeptide and somatostatin.

Forty-seven of the patients were men and 30 were women.

Cerebrospinal fluid samples were obtained from all patients upon myelography.

Levels of the neuropeptides vasoactive intestinal polypeptide and somatostatin were analyzed in a blind manner by radioimmunoassay, using commercially available radioimmunoassay kits.

What Was Measured

PubMed files the paper under topics including Leg, Low Back Pain, Myelography, Radioimmunoassay, Somatostatin, Spinal Nerve Roots and Vasoactive Intestinal Peptide.

What This Means in Plain Language

This is a clinical trial of Somatostatin and VIP (Vasoactive Intestinal Peptide) in 77 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (Spine), a journal based in United States.

More context: the Somatostatin compound page and the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.